JP2019528677A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528677A5 JP2019528677A5 JP2018566591A JP2018566591A JP2019528677A5 JP 2019528677 A5 JP2019528677 A5 JP 2019528677A5 JP 2018566591 A JP2018566591 A JP 2018566591A JP 2018566591 A JP2018566591 A JP 2018566591A JP 2019528677 A5 JP2019528677 A5 JP 2019528677A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- domain
- seq
- composition
- axl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1610902.7A GB201610902D0 (en) | 2016-06-22 | 2016-06-22 | Anti-Axl Antagonistic Antibodies |
| GB1610902.7 | 2016-06-22 | ||
| PCT/EP2017/065313 WO2017220695A1 (en) | 2016-06-22 | 2017-06-21 | Anti-axl antagonistic antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019528677A JP2019528677A (ja) | 2019-10-17 |
| JP2019528677A5 true JP2019528677A5 (enExample) | 2020-07-30 |
| JP7071935B2 JP7071935B2 (ja) | 2022-05-19 |
Family
ID=56895047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018566591A Expired - Fee Related JP7071935B2 (ja) | 2016-06-22 | 2017-06-21 | 抗Ａｘｌアンタゴニスト抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11198734B2 (enExample) |
| EP (1) | EP3475305A1 (enExample) |
| JP (1) | JP7071935B2 (enExample) |
| KR (1) | KR102458196B1 (enExample) |
| CN (2) | CN116903748A (enExample) |
| AU (1) | AU2017281326A1 (enExample) |
| CA (1) | CA3025729A1 (enExample) |
| GB (1) | GB201610902D0 (enExample) |
| MX (1) | MX2018016096A (enExample) |
| WO (1) | WO2017220695A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3233119A2 (en) * | 2014-12-18 | 2017-10-25 | Bergen Teknologioverforing AS | Anti-axl antagonistic antibodies |
| GB201610902D0 (en) * | 2016-06-22 | 2016-08-03 | Bergen Teknologioverforing As And Bergenbio As | Anti-Axl Antagonistic Antibodies |
| CN110483639A (zh) | 2018-05-15 | 2019-11-22 | 复旦大学 | 靶向axl的抗体及抗体-药物偶联物及其制备方法和用途 |
| GB201912059D0 (en) | 2019-08-22 | 2019-10-09 | Bergenbio As | Combaination therapy of a patient subgroup |
| NL2024108B1 (en) * | 2019-10-26 | 2021-07-19 | Vitroscan B V | Methods and apparatus for measuring immune-cell mediated anti-tumoroid responses |
| BR112022015977A2 (pt) * | 2020-02-28 | 2022-10-11 | Symphogen As | Anticorpos anti-axl e composições |
| GB202004189D0 (en) | 2020-03-23 | 2020-05-06 | Bergenbio As | Combination therapy |
| IL297132A (en) | 2020-04-08 | 2022-12-01 | Bergenbio Asa | axl inhibitors for antiviral therapy |
| GB202006072D0 (en) * | 2020-04-24 | 2020-06-10 | Bergenbio Asa | Method of selecting patients for treatment with cmbination therapy |
| MX2023008744A (es) | 2021-01-29 | 2023-10-02 | Illimis Therapeutics Inc | Molecula de fusion que tiene actividad no inflamatoria inductora de la fagocitosis. |
| GB202104037D0 (en) | 2021-03-23 | 2021-05-05 | Bergenbio Asa | Combination therapy |
| EP4357365A4 (en) * | 2021-06-16 | 2025-06-04 | Shanghai Sinobay Biotechnology Co., Ltd. | Antibodies against AXL protein and antigen-binding fragment thereof, as well as methods of production and use thereof |
| EP4359439A1 (en) * | 2021-06-24 | 2024-05-01 | Yeda Research and Development Co. Ltd | Combination therapy for the treatment of cancer comprising an anti-egfr antibody and an axl-inhibitor |
| WO2024040114A2 (en) * | 2022-08-18 | 2024-02-22 | BioLegend, Inc. | Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1382969A1 (en) | 2002-07-17 | 2004-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Diagnosis and prevention of cancer cell invasion |
| CA2705164A1 (en) | 2007-11-12 | 2009-05-22 | U3 Pharma Gmbh | Axl antibodies |
| KR101568051B1 (ko) | 2007-11-15 | 2015-11-10 | 추가이 세이야쿠 가부시키가이샤 | Ａｎｅｘｅｌｅｋｔｏ에 결합하는 단일클론항체, 및 그의 이용 |
| JP5909442B2 (ja) | 2009-05-11 | 2016-04-26 | ユー３・ファーマ・ゲーエムベーハー | ヒト化ａｘｌ抗体 |
| RU2011151069A (ru) | 2009-05-15 | 2013-06-20 | Чугаи Сейяку Кабусики Кайся | Анти-axl антитело |
| TW201106972A (en) | 2009-07-27 | 2011-03-01 | Genentech Inc | Combination treatments |
| CA2794731C (en) * | 2010-06-18 | 2019-03-19 | Genentech, Inc. | Anti-axl antibodies and methods of use |
| JP6033293B2 (ja) | 2011-06-22 | 2016-11-30 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル）Ｉｎｓｅｒｍ（Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅｌａ Ｓａｎｔｅ Ｅｔ Ｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌｅ） | 抗Ａｘｌ抗体及びその使用 |
| US9409988B2 (en) * | 2011-06-22 | 2016-08-09 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anti-Axl antibodies and uses thereof |
| EP2589609A1 (en) | 2011-11-03 | 2013-05-08 | Pierre Fabre Medicament | Antigen binding protein and its use as addressing product for the treatment of cancer |
| CA2890265C (en) * | 2012-11-05 | 2023-01-17 | Pierre Fabre Medicament | Antigen binding proteins and their use as addressing product for the treatment of cancer |
| WO2014144553A1 (en) * | 2013-03-15 | 2014-09-18 | Amgen Inc. | Secreted frizzle-related protein 5 (sfrp5) binding proteins and methods of treatment |
| US20160106861A1 (en) | 2013-04-26 | 2016-04-21 | Spirogen Sarl | Axl antibody-drug conjugate and its use for the treatment of cancer |
| MX380864B (es) * | 2014-01-29 | 2025-03-12 | Dana Farber Cancer Inst Inc | Anticuerpos contra el dominio extracelular de muc1-c (muc1-c/ecd). |
| GB201410826D0 (en) | 2014-06-18 | 2014-07-30 | Bergenbio As | Anti-axl antibodies |
| GB201410825D0 (en) | 2014-06-18 | 2014-07-30 | Bergenbio As | Anti-axl antibodies |
| US9986723B2 (en) | 2014-10-22 | 2018-06-05 | The Board Of Regents Of The University Of Texas System | Screen and use of therapeutics for pancreatic ductal adenocarcinoma |
| EP3229836B1 (en) | 2014-12-09 | 2019-11-13 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Human monoclonal antibodies against axl |
| EP3233119A2 (en) | 2014-12-18 | 2017-10-25 | Bergen Teknologioverforing AS | Anti-axl antagonistic antibodies |
| GB201610902D0 (en) * | 2016-06-22 | 2016-08-03 | Bergen Teknologioverforing As And Bergenbio As | Anti-Axl Antagonistic Antibodies |
| US11159088B2 (en) * | 2019-06-19 | 2021-10-26 | Appulse Power Inc. | Dual path and mode start-up circuit |
| GB202004189D0 (en) * | 2020-03-23 | 2020-05-06 | Bergenbio As | Combination therapy |
-
2016
- 2016-06-22 GB GBGB1610902.7A patent/GB201610902D0/en not_active Ceased
-
2017
- 2017-06-21 CA CA3025729A patent/CA3025729A1/en active Pending
- 2017-06-21 CN CN202310799984.3A patent/CN116903748A/zh active Pending
- 2017-06-21 EP EP17732875.4A patent/EP3475305A1/en not_active Withdrawn
- 2017-06-21 KR KR1020187036968A patent/KR102458196B1/ko active Active
- 2017-06-21 CN CN201780038590.9A patent/CN109311997B/zh not_active Expired - Fee Related
- 2017-06-21 WO PCT/EP2017/065313 patent/WO2017220695A1/en not_active Ceased
- 2017-06-21 MX MX2018016096A patent/MX2018016096A/es unknown
- 2017-06-21 US US16/098,933 patent/US11198734B2/en not_active Expired - Fee Related
- 2017-06-21 AU AU2017281326A patent/AU2017281326A1/en not_active Abandoned
- 2017-06-21 JP JP2018566591A patent/JP7071935B2/ja not_active Expired - Fee Related
-
2021
- 2021-11-02 US US17/516,916 patent/US11732048B2/en active Active
-
2023
- 2023-06-29 US US18/216,085 patent/US20240190972A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018506961A5 (enExample) | ||
| JP2022177090A5 (enExample) | ||
| PE20240218A1 (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 | |
| HRP20241381T1 (hr) | Nova anti-pd-1 protutijela | |
| JP2019107018A5 (enExample) | ||
| JP2015517300A5 (enExample) | ||
| JP2017524715A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| JP2017514461A5 (enExample) | ||
| JP2012254092A5 (enExample) | ||
| JP2013519364A5 (enExample) | ||
| JP2015163068A5 (enExample) | ||
| IL273841B1 (en) | Antibodies targeting cd137 and methods of use thereof | |
| AR102698A1 (es) | Anticuerpos contra cd73 y sus usos | |
| JP2020504076A5 (enExample) | ||
| JP2020516305A5 (enExample) | ||
| AR108034A1 (es) | Moléculas de unión a ror1, y métodos de uso de las mismas | |
| JP2017176174A5 (enExample) | ||
| JP2017048240A5 (enExample) | ||
| JP2018517431A5 (enExample) | ||
| JP2018536393A5 (enExample) | ||
| JP2020501598A5 (enExample) | ||
| JP2017526339A5 (enExample) | ||
| JP2017521054A5 (enExample) | ||
| JP2012519492A5 (enExample) |